En
Búsqueda avanzada
Bibliografía

Guía de Práctica Clínica sobre la detección y el manejo de la Enfermedad Renal Crónica
Completa HTML



    1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39 (2 Suppl 1):S1-266.
    2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter., Suppl. 2013;3:1–150.
    3. Engelgau MM, El-Saharty S, Kudesia P, et al. Regional aging and disease burden. In: Capitalizing on the demographic transition: tackling noncommunicable diseases in South Asia. Washington, DC: World Bank. 2011:15–40.
    4. Ayodele OE, Alebiosu CO. Burden of chronic kidney disease: an international perspective. Adv Chronic Kidney Dis. 2010;17:215–24.
    5. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380:2095–128.
    6. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet. 2010;375:1296–309.
    7. Feehally J. Ethnicity and renal disease. Kidney Int. 2005;68:414–24.
    8. McDonald SP, Maguire GP, Hoy WE. Renal function and cardiovascular risk markers in a remote Australian Aboriginal community. Nephrol Dial Transplant. 2003;18:1555–61.
    9. Ashton CW, Duffie D. Chronic kidney disease in Canada’s First Nations: results of an eff ective cross-cultural collaboration. Healthcare Q. 2011;14:42–7.
    10. Rajapurkar MM, John GT, Kirpalani AL, et al. What do we know about chronic kidney disease in India: first report of the Indian CKD registry. BMC Nephrol. 2012;13:10.
    11. Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379:815–22.
    12. White SL, Chadban SJ, Jan S, et al. How can we achieve global equity in provision of renal replacement therapy? Bull World Health Organ. 2008;86:229–37.
    13. Otero A, de Francisco A, Gayoso P, et al. EPIRCE Study Group. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrologia. 2010;30(1):78-86
    14. Van der Velde M, Matsushita K, Coresh J, et al, for the Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with all cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341–52.
    15. Matsushita K, van der Velde M, Astor BC, et al, for the CKD Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375: 2073–81.
    16. Martinez-Castelao A, Gorriz JL, Portoles JM, et al. Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study. BMC Nephrol. 2011;12:53.
    17. National Collaborating Centre for Chronic Conditions. Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care. London: Royal College of Physicians, September 2008.
    18. Levey AS, de Jong PE, Coresh J et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17–28.
    19. Martínez-Castelao A, Górriz JL, Bover J, et al. Documento de consenso para la detección y manejo de la enfermedad renal crónica. Nefrologia. 2014;34(2):243-62
    20. Montañés Bermúdez R, Gracia García S, Pérez Surribas D, et al. Sociedad Española de Bioquímica Clínica y Patología Molecular; Sociedad Española de Nefrología. Documento de Consenso. Recomendaciones sobre la valoración de la proteinuria en el diagnóstico y seguimiento de la enfermedad renal crónica. Nefrologia. 2011;31(3):331-45.
    21. Grupo de trabajo sobre GPC. Elaboración de Guías de Práctica Clínica en el Sistema Nacional de Salud. Manual Metodológico. Madrid: Plan Nacional para el SNS del MSC. Instituto Aragonés de Ciencias de la Salud-I+CS; 2007. Guías de Práctica Clínica en el SNS: I+CS Nº 2006/0I.
    22. Guyatt GH, Oxman AD, Vist G, et al, for the GRADE Working Group. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-6.
    23. Alonso-Coello P, Rigau D, Sanabria AJ, et al. Quality and strength: The GRADE system for formulating recommendations in clinical practice guidelines. Arch Bronconeumol. 2013;49(6): 261-7.
    24. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. Value in health. 2013;16:e1–e5.
    25. Fretheim A, Schünemann HJ, Oxman AD. Improving the use of research evidence in guideline development: 3. Group composition and consultation process. Health Res Policy System. 2006;4:15
    26. Jaeschke Roman, Guyatt Gordon H, Dellinger Phil, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive BMJ. 2008;337:a744
    27. Komenda P, Ferguson TW, Macdonald K, et al. Cost-effectiveness of primary screening for CKD: a systematic review. Am J Kidney Dis. 2014;63(5):789-97
    28. Hoerger TJ, Wittenborn JS, Segel JE, et al. Centers for Disease Control and Prevention CKD Initiative. A health policy model of CKD. Part 2: The cost€effectiveness of microalbuminuria screening. Am J Kidney Dis. 2010;55(3):463-73.
    29. Boulware LE, Jaar BG, Tarver-Carr ME, et al. Screening for proteinuria in US adults: a costeffectiveness analysis. JAMA. 2003;290(23):3101-14.
    30. Palmer A J, Valentine W J, Chen R, et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant. 2008;23(4):1216-23.
    31. Manns B, Hemmelgarn B, Tonelli M, et al. Population based screening for chronic kidney disease: cost effectivess study. BMJ. 2010;341:c5869
    32. Boersma C, Gansevoort RT, Pechlivanoglou P, et al. Prevention of Renal and Vascular End Stage Disease Study Group. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands. Clin Ther. 2010;32(6):1103-21.
    33. Pignone MP, Howard K, Brenner AT, et al. Comparing 3 techniques for eliciting patient values for decision making about prostate-specific antigen screening: a randomized controlled trial. JAMA Intern Med. 2013;173(5):362-8.
    34. Kessler R, Keusch G, Szucs TD, et al. Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland. Swiss Med Wkly. 2012;142:w13508.
    35. Howard K, White S, Salkeld G, et al. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis. Value Health. 2010;13(2):196-208.
    36. Kondo M, Yamagata K, Hoshi SL, et al. Cost-effectiveness of chronic kidney disease mass screening test in Japan. Clin Exp Nephrol. 2012;16(2):279-91.
    37. Siegel JE, Krolewski AS, Warram JH, et al. Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. J Am Soc Nephrol. 1992;3(4)(suppl 1):S111-S119.
    38. Castaneda C, Gordon PL, Uhlin KL, et al. Resistance training to counteract the catabolism of a low-protein diet in patients with chronic renal insufficiency. A randomized, controlled trial. Ann Intern Med. 2001;135(11):965-76.
    39. Eidemak I, Haaber AB, Feldt-Rasmussen B, et al. Exercise training and the progression of chronic renal failure. Nephron. 1997;75(1):36-40.
    40. Flesher M, Woo P, Chiu A, et al. Self-management and biomedical outcomes of a cooking, and exercise program for patients with chronic kidney disease. J Ren Nutr. 2011;21(2):188-95.
    41. Headley S, Germain M, Milch C, et al. Exercise training improves HR responses and V˙O2peak in predialysis kidney patients. Med Sci Sports Exerc. 2012;44(12):2392-9.
    42. Heiwe S, Jacobson SH. Exercise training for adults with chronic kidney disease. Cochrane Database Syst Rev. 2011, Issue 10. Art. No.: CD003236.
    43. Howden EJ, Fassett RG, Isbel NM, et al. Exercise training in chronic kidney disease patients. Sports Med. 2012;42(6):473-88.
    44. Kosmadakis GC, John SG, Clapp EL, et al. Benefits of regular walking exercise in advanced pre-dialysis chronic kidney disease. Nephrol Dial Transplant. 2012;27(3):997-1004.
    45. Leehey DJ, Moinuddin I, Bast JP, et al. Aerobic exercise in obese diabetic patients with chronic kidney disease: a randomized and controlled pilot study. Cardiovasc Diabetol. 2009;8:62.
    46. Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2(1):e004473.
    47. Chudyk A, Petrella RJ. Effects of exercise on cardiovascular risk factors in type 2 diabetes: a meta-analysis. Diabetes Care. 2011;34(5):1228-37.
    48. Davies EJ, Moxham T, Rees K, et al. Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis. Eur J Heart Fail. 2010;12(7):706-15.
    49. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004;116(10):682-92.
    50. Dale PL, Hutton J, Elgazzar H. Utility of health states in chronic kidney disease: a structured review of the literature. Curr Med Res Opin. 2008;24:193.
    51. Wyld M, Morton RL, Hayden A, et al. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLOS Medicine. 2012;9(9):e1001307.
    52. Liem YS, Bosch JL, Hunink MGM. Preference-based quality of life of patients on renal replacement therapy; a systematic review and meta-analysis. Value in health. 2008;11:733-41.
    53. Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68:2801-8.
    54. Revicki DA. Relationship between health utility and psychometric health status measures. Med Care. 1992;30(5s):MS274-MS282.
    55. Wang Y, Chen X, Song Y et al. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008;73:19–33.
    56. Afshinnia F, Wilt TJ, Duval S, et al. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant. 2010;25(4):1173-83.
    57. Navaneethan SD, Yehnert H, Moustarah F, et al. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(10):1565-74.
    58. Morales E, Valero MA, León M, et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 2003;41:319–27.
    59. Praga M, Hernández E, Andrés A, et al. Effects of body-weight loss and captopril treatment on proteinuria associated with obesity. Nephron. 1995;70:35–41.
    60. Tirosh A, Golan R, Harman-Boehm I, et al. Renal function following three distinct weight loss dietary strategies during 2 years of a randomized controlled trial. Diabetes Care. 2013; 36(8):2225-32.
    61. McGee DL; Diverse Populations Collaboration. Body mass index and mortality: a metaanalysis based on person-level data from twenty-six observational studies. Ann Epidemiol. 2005;15(2):87-97.
    62. Avenell A, Broom J, Brown TJ, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technology Assessment (Winchester, England). 2004;8(21):iii-iiv.
    63. Mori T, Burke V, Puddey I, et al. The effects of omega3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. Journal of Hypertension. 2009;27:1863–72.
    64. Vedtofte MS, Jakobsen MU, Lauritzen L, et al. The role of essential fatty acids in the control of coronary heart disease. Curr Opin Clin Nutr Metab Care. 2012;15(6):592-6.
    65. Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2010;7(3):e1000252.
    66. Fouque D, Laville M. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev. 2009, Issue 3. Art. No.: CD001892.
    67. Cianciaruso B, Andrea, Bellizzi V, et al. Effect of a Low Versus Moderate Protein Diet on Progression of CKD: Follow-up of a Randomized Controlled Trial, American Journal of Kidney Diseases. 2009;54(6):1052-61.
    68. Menon V, Kopple JD, Wang X, et al. Effect of a very low-protein diet on outcomes: longterm follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis. 2009;53(2):208-17.
    69. Robertson LM, Waugh N, Robertson A. Protein restriction for diabetic renal disease. Cochrane Database Syst Rev. 2007, Issue 4. Art. No.: CD002181.
    70. Koya D, Haneda M, Inomata S. Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomized controlled trial. Diabetologia. 2009;52:2037-45.
    71. Jones-Burton Ch, Mishra S, Fink J, el al. An In-Depth Review of the Evidence Linking Dietary Salt Intake and Progression of Chronic Kidney Disease. Am J Nephrol. 2006;26:268–75.
    72. Yoshioka K, Imanishi M, Konishi Y, et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care. 1998;21(4):482-6.
    73. Vedovato M, Lepore G, Coracina A, et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia. 2004; 47(2):300-3.
    74. Weir MR, Dengel DR, Behrens MT, et al. Salt-induced increases in systolic blood pressure affect renal hemodynamics and proteinuria. Hypertension. 199;25(6):1339-44.
    75. Krikken A, Laverman G, Navis G, Benefits of dietary sodium restriction in the management of chronic kidney disease. Current Opinion in Nephrology and Hypertension. 2009,18:531–8.
    76. Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens. 2006;24:215–33.
    77. Hooper L, Bartlett C, Davey Smith G, et al. Systematic review of long term effects of advice to reduce dietary salt in adults. BMJ. 2002;325:628.
    78. Thomas MC, Moran J, Forsblom C, et al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabetes Care. 2011;34:861–6.
    79. McMahon EJ, Bauer JD, Hawley CM, et al. A randomized trial of dietary sodium restriction in CKD. J Am Soc Nephrol. 2013;24(12):2096-103.
    80. Aburto NJ, Hanson S, Gutierrez H, et al. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ. 2013;346:f1378.
    81. O’Donnell M, Mente A, Rangarajan S, et al. PURE Investigators. Urinary sodium and potassium excretion, mortality, and cardiovascular events.N Engl J Med. 2014;371(7):612-23.
    82. Chuahirun T, Simoni J, Hudson C, et al. Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes. Am J Med Sci. 2004;327 (2):57-7.
    83. Phisitkul K, Hegazy K, Chuahirun T, et al. Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy. Am J Med Sci. 2008;335(4):284- 91.
    84. U.S. Department of Health and Human Services.The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014 [acceso 6 de febrero de 2014].
    85. U.S. Department of Health and Human Services. How Tobacco Smoke Causes Disease: What It Means to You. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2010 [acceso 6 de febrero de 2014].
    86. Paech D, Mernagh P and Weston A. A systematic review of economic evaluations for tobacco control programs. HSAC Report. 2010;3(17).
    87.  Susantitaphong P, Sewaralthahab K, Balk EM, et al. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a metaanalysis. Am J Hypertens. 2013;26(3):424-41.
    88. Fink HA, Ishani A, Taylor BC, et al. Chronic Kidney Disease Stages 1–3: Screening, Monitoring, and Treatment. Comparative Effectiveness Review No. 37. (Prepared by the Minnesota Evidence-based Practice Center under Contract No. HHSA 290-2007-10064-I.) AHRQ Publication No. 11(12)-EHC075-EF. Rockville, MD: Agency for Healthcare Research and Quality. January 2012. www.effectivehealthcare.ahrq.gov/reports/final.cfm.
    89. Sharma P, Blackburn RC, Parke CL, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst Rev. 2011;(10):CD007751.
    90. Sarafidis PA, Stafylas PC, Kanaki AI, et al. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. Am J Hypertens. 2008;21(8):922-9.
    91. Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a metaanalysis. Am Heart J. 2008;155(5):791-805.
    92. Strippoli GF, Bonifati C, Craig M, et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006, Issue 4. Art. No.: CD006257.
    93. Imai E, Chan JC, Ito S, et al. ORIENT study investigators. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54(12):2978-86.
    94. Mann JF, Anderson C, Gao P, et al. ONTARGET investigators. Dual inhibition of the reninangiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. J Hypertens. 201;31(2):414-21.
    95. Ernst ME, Moser M. Use of Diuretics in Patients with Hypertension N Engl J Med. 2009;361: 2153-64.
    96. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360:1903–13. 7.
    97. Astor BC, Matsushita K, Gansevoort RT et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011; 79: 1331–40.
    98. Gansevoort RT, Matsushita K, van der Velde M et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011;80:93–104.
    99. Badve SV, Roberts MA, Hawley CM, et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58:1152–61.
    100. Asselbergs FW, Diercks GFH, Hillege HL, et al. Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110(18):2809-16
    101. O’Hare P, Bilbous R, Mitchell T, et al. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care. 2000;23(12):1823–9.
    102. Crepaldi G, Carta Q, Deferrari G, et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care. 1998;21(1):104-10.
    103. Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. American Journal of Medicine. 1995;99(5):497- 504.
    104. Sano T, Kawamura T, Matsumae H, et al. Effects of long-term enalapril treatment on persistent micro-albuminuria in well controlled hypertensive and normotensive NIDDM patients. Diabetes Care. 1994;17(5):420-4.
    105. Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118(8):577-81.
    106. Bojestig M, Karlberg BE, Lindstrom T, et al. Reduction of ACE activity is insuficient to decrease microalbuminuria in normotensive patients with type 1 diabetes. Diabetes Care. 2001;24(5):919-24.
    107. Stafylas PC, Sarafidis PA, Lasaridis AN, et al. Cost-effectiveness of losartan in diabetic nephropathy: a Greek perspective. Journal of Nephrology. 2007;20(6):703-15.
    108. Adarkwah CC, Gandjour A, Akkerman M, Evers S. To Treat or Not to Treat? Cost-Effectiveness of Ace Inhibitors in Non-Diabetic Advanced Renal Disease – a Dutch Perspective. Kidney Blood Press Res 2013;37:168-80.
    109. Centre for Reviews and Dissemination. [Critically appraised economic evaluations] Costeffectiveness of angiotensin€converting enzyme inhibitors in nondiabetic advanced renal disease (Structured abstract). NHS Economic Evaluation Database (NHSEED) 2013 Issue 4.
    110. Adarkwah CC, Gandjour A. Cost€effectiveness of angiotensin€converting enzyme inhibitors in nondiabetic advanced renal disease. Expert Review of Pharmacoeconomics and Outcomes Research. 2011;11(2):215€23.
    111. Hou FF, Zhang X, Zhang GH et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006(354):131–40.
    112. Ihle BU, Whitworth JA, Shahinfar S, et al. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis. 1996(27):489–9.
    113. Adarkwah CC, Gandjour A, Akkerman M, et al. To Treat or Not to Treat? Cost-Effectiveness of Ace Inhibitors in Non-Diabetic Advanced Renal Disease – a Dutch Perspective. Kidney Blood Press Res. 2013;37:168-80.
    114. Powers BJ, Coeytaux RR, Dolor RJ, et al. Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information. J Gen Intern Med. 2012;27(6):716-29.
    115. Fernandez Juarez G, Luño J, Barrio V, et al. PRONEDI Study Group. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. Am J Kidney Dis. 2013;61(2):211-8.
    116. Mann JFE, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547-53.
    117. Sipahi I, Debanne SM, Rowland DY, et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11(7):627-36.
    118. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomized trials. Lancet Oncol. 2011;12:65-82.
    119. The ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, and candesartan, and losartan on cancers in 15 trials. J Hypertens. 2011;29:623-35.
    120. Pasternak B, Svanström H, Callréus T, et al. Use of angiotensin receptor blockers and the risk of cancer. Circulation. 2011;123:1729-36.
    121. Adarkwah CC, Gandjour A. Cost-effectiveness of angiotensin-converting enzyme inhibitors in nondiabetic advanced renal disease. Expert Rev Pharmacoecon Outcomes Res. 2011;11(2): 215-23.
    122. Fried LF, Emanuele N, Zhang JH, et al. VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892-903.
    123. Anand IS, Bishu K, Rector TS, et al. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation. 2009;120(16):1577-84.
    124. Tobe SW, Clase CM, Gao P, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation. 2011;123(10):1098-107.
    125. Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev 2013, Issue 10. Art. No.: CD008277.
    126. Royal College of Physicians. Chronic kidney diseases in adults: UK guidelines for identification, management and referral. London: RCP, 2006.
    127. Scottish Intercollegiate Guidelines Network. Chronic Kidney Disease. Edinburgh: SIGN, 2008. (SIGN publication no. 103).
    128. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. Journal of Human Hypertension. 2004;18(3):139-85.
    129. Lewis JB, Berl T, Bain RP, et al. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. American Journal of Kidney Diseases. 1999;34(5):809-17.
    130. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123(10):754-62.
    131. Barylski M, Nikfar S, Mikhailidis DP, et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy: a meta-analysis of 11 randomized controlled trials involving 21295 participants. Pharmacol Res. 2013;72:35-44.
    132. Hou W, Lv J, Perkovic V, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J. 2013;34(24):1807-17.
    133. Upadhyay A, Earley A, Lamont JL, et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012; 157(4):251-62.
    134. Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012; 157(4):263-75.
    135. Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009; (2):CD007784.
    136. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336(7645):645-51.
    137. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-92.
    138. Dormuth CR, Hemmelgarn BR, Paterson JM, et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ. 2013;346:f880.
    139. Erickson KF, Japa S, Owens DK, et al. Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease. J Am Coll Cardiol. 2013;61(12):1250-8.
    140. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-305.
    141. Palmer SC, Di Micco L, Razavian M, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2013, Issue 4. Art. No.: CD008834.
    142. Antithrombotic Trialists’ Collaboration: Collaborative meta-analysis of randomised trials for prevention of death, myocardial infarction, and stroke in high risk patients BMJ. 2002; 324(7329):71-86.
    143. Holden RM, Harman GJ, Wang M, et al. Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(1):105-10.
    144. MacLean S, Mulla S, Akl E, et al. Patient Values and Preferences in Decision Making for Antithrombotic Therapy: A Systematic Review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2):e1S-e23S.
    145. Li T, Wu HM, Wang F, et al. Education programmes for people with diabetic kidney disease. Cochrane Database Syst Rev 2011, Issue 6. Art. No.: CD007374.
    146. Strand H, Parker D. Effects of multidisciplinary models of care for adult pre-dialysis patients with chronic kidney disease: a systematic review. Int J Evid Based Healthc. 2012;10(1):53-9.
    147. Mason J, Khunti K, Stone M, et al. Educational interventions in kidney disease care: a systematic review of randomized trials. Am J Kidney Dis. 2008;51(6):933-51.
    148. Chen SH, Tsai YF, Sun CY, et al. The impact of self-management support on the progression of chronic kidney disease: a prospective randomized controlled trial. Nephrol Dial Transplant. 2011;26(11):3560-6.
    149. Sabariego C, Grill E, Brach M, et al. Incremental cost-effectiveness analysis of a multidisciplinary renal education program for patients with chronic renal disease. Disabil Rehabil. 2010;32(5):392-401.
    150. Stacey D, Légaré F, Col NF, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2014, Issue 1. Art. No.: CD001431.
    151. Hermosilla Gago T, Quirós Ganga PL, Remón Rodríguez C, et al, Grupo ERC. Tool to assist in the decision-making of patients susceptible to dialysis (Structured abstract). Health Technology Assessment Database. 2011;(1).
    152. Clinical practice guidelines on shared decision-making in the appropriate initiation of and withdrawal from dialysis. Renal Physicians Association/American Society of Nephrology Working Group. J Am Soc Nephrol. 2000;11(9):2 p following 1788.
    153. Moss AH. Shared Decision Making in dialysis: a new clinical practice guideline to assist with dialysis-related ethics consultations. J Clin Ethics. 2001;12(4):406-14.
    154. Moss AH. Shared decision-making in dialysis: the new RPA/ASN guideline on appropriate initiation and withdrawal of treatment. Am J Kidney Dis. 2001;37(5):1081-91.
    155. Patel SS, Holley JL. Withholding and withdrawing dialysis in the intensive care unit: benefits derived from consulting the renal physicians association/american society of nephrology clinical practice guideline, shared decision-making in the appropriate initiation of and withdrawal from dialysis. Clin J Am Soc Nephrol. 2008;3(2):587-93.
    156. Registered Nurses’ Association of Ontario. Decision Support for Adults Living with Chronic Kidney Disease. Toronto,Canada. Registered Nurses’ Association of Ontario (2009).
    157. Morton RL, Tong A, Howard K, et al. The views of patients and carers in treatment decision making for chronic kidney disease: systematic review and thematic synthesis of qualitative studies. BMJ. 2010;340:c112.
    158. Smart NA, Titus TT. Outcomes of early versus late nephrology referral in chronic kidney disease: a systematic review. Am J Med. 2011;124(11):1073-80.
    159. Black C, Sharma P, Scotland G, et al. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, costeffectiveness and economic analysis. Health Technol Assess. 2010;14(21):1-184.
    160. Chan MR, Dall AT, Fletcher KE, et al. Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis. Am J Med. 2007;120(12):1063-70.
    161. AHRQ Agency for healthcare research and quality. Medicines for Early Stage Chronic Kidney Disease. A Review of the Research for Adults With Kidney Disease and Diabetes or High Blood Pressure. 2012 Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK114445/f.
    162. NICE National Institute for Health and Care Excellence. Identifying and treating long-term kidney problems (chronic kidney disease). 2008 Sep.
    163. Guyatt GH, Oxman AD, Vist G, et al, for the GRADE Working Group. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-6.
    164. Guyatt GH, Oxman AD, Kunz R, et al; GRADE Working Group. Rating quality of evidence and strength of recommendations: What is “quality of evidence” and why is it important to clinicians? BMJ. 2008;336(7651):995-8.
    165. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines 3: rating the quality of evi dence. J Clin Epidemiol. 2011;64:401-6.
    166. Andrews JC, Schünemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation’s direction and strength. J Clin Epidemiol. 2013;66(7):726-35.
    167. Guyatt G, Oxman AD, Sultan S, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol. 2013;66(2):151-7.
    168. Alonso-Coello P, Rigau D, Solà I, et al. La formulación de recomendaciones en salud: el sistema GRADE. MedClin (Barc). 2013;140(8):366-73.
    169. Alonso-Coello P, Rigau D, Sanabria AJ, et al. Quality and strength: the GRADE system for formulating recommendations in clinical practice guidelines. Arch Bronconeumol. 2013;49 (6):261-7.
12. Anexos
¿Esta guía sobre la detección y el manejo de la ERC va dirigida a mí?